Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Alvotech Makes It Four With Denosumab Trial

Study Begins For Firm’s AVT03 Proposed Prolia/Xgeva Biosimilar

Executive Summary

Alvotech has begun its fourth biosimilar clinical trial program, announcing the start of studies for its AVT03 proposed denosumab rival to Prolia/Xgeva.

You may also be interested in...



Sandoz’s High-Concentration Humira Biosimilar Lands On FDA’s Desk

Sandoz has named its three most promising upcoming biosimilar launches, ahead of filing its proposed high-concentration version of adalimumab with the US Food and Drug Administration.

Alvotech Kicks Off Trials For Eylea Biosimilar

Alvotech has announced the start of clinical trials for its AVT06 proposed aflibercept biosimilar rival to Eylea, joining a host of other developers pursuing the same target.

Henlius Denosumab Biosimilar Trial Enters Phase III

Henlius has administered the first dose in its international Phase III trial into its denosumab biosimilar candidate, HLX14. The firm has also revealed that its new Songjiang plant has been granted GMP equivalence with EU practices.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

GB152042

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel